Literature DB >> 24900653

Azaindole-Based Inhibitors of Cdc7 Kinase: Impact of the Pre-DFG Residue, Val 195.

Yunsong Tong1, Kent D Stewart1, Alan S Florjancic1, John E Harlan1, Philip J Merta1, Magdalena Przytulinska1, Nirupama Soni1, Kerren K Swinger1, Haizhong Zhu1, Eric F Johnson1, Alexander R Shoemaker1, Thomas D Penning1.   

Abstract

To investigate the role played by the unique pre-DFG residue Val 195 of Cdc7 kinase on the potency of azaindole-chloropyridines (1), a series of novel analogues with various chloro replacements were synthesized and evaluated for their inhibitory activity against Cdc7. X-ray cocrystallization using a surrogate protein, GSK3β, and modeling studies confirmed the azaindole motif as the hinge binder. Weaker hydrophobic interactions with Met 134 and Val 195 by certain chloro replacements (e.g., H, methyl) led to reduced Cdc7 inhibition. Meanwhile, data from other replacements (e.g., F, O) indicated that loss of such hydrophobic interaction could be compensated by enhanced hydrogen bonding to Lys 90. Our findings not only provide an in-depth understanding of the pre-DFG residue as another viable position impacting kinase inhibition, they also expand the existing knowledge of ligand-Cdc7 binding.

Entities:  

Keywords:  Cdc7 kinase; azaindole; pre-DFG residue

Year:  2013        PMID: 24900653      PMCID: PMC4027468          DOI: 10.1021/ml300348c

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  24 in total

1.  Drf1, a novel regulatory subunit for human Cdc7 kinase.

Authors:  A Montagnoli; R Bosotti; F Villa; M Rialland; D Brotherton; C Mercurio; J Berthelsen; C Santocanale
Journal:  EMBO J       Date:  2002-06-17       Impact factor: 11.598

2.  QSAR models for predicting the similarity in binding profiles for pairs of protein kinases and the variation of models between experimental data sets.

Authors:  Robert P Sheridan; Kiyean Nam; Vladimir N Maiorov; Daniel R McMasters; Wendy D Cornell
Journal:  J Chem Inf Model       Date:  2009-08       Impact factor: 4.956

3.  The Cdc7 protein kinase is required for origin firing during S phase.

Authors:  K Bousset; J F Diffley
Journal:  Genes Dev       Date:  1998-02-15       Impact factor: 11.361

4.  Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication.

Authors:  W Jiang; D McDonald; T J Hope; T Hunter
Journal:  EMBO J       Date:  1999-10-15       Impact factor: 11.598

5.  Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases.

Authors:  Alessia Montagnoli; Barbara Valsasina; Deborah Brotherton; Sonia Troiani; Sonia Rainoldi; Pierluigi Tenca; Antonio Molinari; Corrado Santocanale
Journal:  J Biol Chem       Date:  2006-01-30       Impact factor: 5.157

6.  CDC7 kinase phosphorylates serine residues adjacent to acidic amino acids in the minichromosome maintenance 2 protein.

Authors:  Won-Ho Cho; Young-Joo Lee; Soo-Im Kong; Jerard Hurwitz; Joon-Kyu Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

7.  4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors.

Authors:  Cynthia M Shafer; Mika Lindvall; Cornelia Bellamacina; Thomas G Gesner; Asha Yabannavar; Weiping Jia; Song Lin; Annette Walter
Journal:  Bioorg Med Chem Lett       Date:  2008-07-17       Impact factor: 2.823

8.  Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis.

Authors:  Danzhi Huang; Ting Zhou; Karine Lafleur; Cristina Nevado; Amedeo Caflisch
Journal:  Bioinformatics       Date:  2009-11-26       Impact factor: 6.937

9.  Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation.

Authors:  Dorine Bonte; Charlotta Lindvall; Hongyu Liu; Karl Dykema; Kyle Furge; Michael Weinreich
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

10.  Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.

Authors:  Antonella Ermoli; Alberto Bargiotti; Maria Gabriella Brasca; Antonella Ciavolella; Nicoletta Colombo; Gabriele Fachin; Antonella Isacchi; Maria Menichincheri; Antonio Molinari; Alessia Montagnoli; Antonio Pillan; Sonia Rainoldi; Federico Riccardi Sirtori; Francesco Sola; Sandrine Thieffine; Marcellino Tibolla; Barbara Valsasina; Daniele Volpi; Corrado Santocanale; Ermes Vanotti
Journal:  J Med Chem       Date:  2009-07-23       Impact factor: 7.446

View more
  5 in total

1.  Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor Series.

Authors:  Joachim Rudolph; Ignacio Aliagas; James J Crawford; Simon Mathieu; Wendy Lee; Qi Chao; Ping Dong; Lionel Rouge; Weiru Wang; Christopher Heise; Lesley J Murray; Hank La; Yanzhou Liu; Gerard Manning; François Diederich; Klaus P Hoeflich
Journal:  ACS Med Chem Lett       Date:  2015-05-20       Impact factor: 4.345

2.  Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.

Authors:  Chengbin Yang; Xi Zhang; Yi Wang; Yongtai Yang; Xiaofeng Liu; Mingli Deng; Yu Jia; Yun Ling; Ling-Hua Meng; Yaming Zhou
Journal:  ACS Med Chem Lett       Date:  2017-07-26       Impact factor: 4.345

3.  Discovery of Azaindolin-2-One as a Dual Inhibitor of GSK3β and Tau Aggregation with Potential Neuroprotective Activity.

Authors:  Taha F S Ali; Halil I Ciftci; Mohamed O Radwan; Eslam Roshdy; Ahmed M Shawky; Mohammed A S Abourehab; Hiroshi Tateishi; Masami Otsuka; Mikako Fujita
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-31

4.  Development of a potent and selective chemical probe for the pleiotropic kinase CK2.

Authors:  Carrow I Wells; David H Drewry; Julie E Pickett; Amelie Tjaden; Andreas Krämer; Susanne Müller; Laszlo Gyenis; Daniel Menyhart; David W Litchfield; Stefan Knapp; Alison D Axtman
Journal:  Cell Chem Biol       Date:  2021-01-22       Impact factor: 8.116

Review 5.  The azaindole framework in the design of kinase inhibitors.

Authors:  Jean-Yves Mérour; Frédéric Buron; Karen Plé; Pascal Bonnet; Sylvain Routier
Journal:  Molecules       Date:  2014-11-28       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.